ClinicalTrials.gg
CompletedNCT02279953Updated May 24, 2017

Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder

A Phase 3 interventional study of Vortioxetine 10-20 mg and Placebo in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed at 17 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-05-24.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
35th of 54
151 · median 413
Started
2014
with 3 others
Phase 3
31 of 54
1 open now
Registered
25th of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 35th largest by enrollment, is one of 4 that started in 2014, is one of 31 in phase 3, and was the 25th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

To assess the efficacy of vortioxetine (10 to 20 mg/day) as adjunctive treatment to stable selective serotonin reuptake inhibitor (SSRI) dose versus stable SSRI monotherapy on cognitive performance (focusing on the aspect concerning speed of processing, executive functioning and attention) in patients who are in partial or full remission from their Major Depressive Episode (MDE).

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has achieved either partial (some symptoms of a MDE are present but full criteria are not met) or full remission of major depressive disorder (MDD), diagnosed according to ™.
  • The patient has HAMD-17 total score ≤10.
  • The patient has received SSRI monotherapy for the MDE from which the patient is currently in full or partial remission for ≥12 weeks at licensed doses and been on stable dose ≥8 weeks prior to Screening Visit.
  • The patient has ≥50% response to current SSRI treatment (Antidepressant Treatment Response Questionnaire [ATRQ]).
  • The patient has a PDQ-D total score >25.
  • The patient is a man or woman, aged ≥18 and ≤65 years.

Exclusion criteria

Exclusion Criteria:

  • The patient has a score ≥70 on the DSST (numbers of correct symbols) at the Baseline Visit.
  • The patient is, in the opinion of the investigator, not able to complete the neuropsychological tests validly at the Baseline Visit.
  • The patient has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
  • The patient is diagnosed with reading disability (dyslexia).
  • The patient has a history of lack of response to previous adequate treatment with vortioxetine.
  • The patient has any current psychiatric disorder or Axis I disorder (according to ™ criteria) other than MDD, as assessed using Mini International Neuropsychiatric Interview (MINI).
  • The patient has a current or has had a diagnosis of dysthymic disorder within 3 months preceding the onset of the depressive episode from which the patient is currently in full or partial remission (DSM-IV-TR™ criteria).
  • The patient has borderline, schizotypal, schizoid, paranoid, histrionic, antisocial personality disorders (axis II) as comorbid or primary diagnosis (DSM-IV-TR™ criteria).
  • The patient suffers from personality disorders, mental retardation, pervasive development disorder, attention-deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).
  • The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features (DSM-IV-TR™ criteria).

Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Vortioxetine 10-20 mg

    daily, encapsulated, orally

    Drug: Vortioxetine 10-20 mg · Drug: Placebo

  • Experimental
    Vortioxetine 10-20 mg + SSRI

    daily, encapsulated, orally

    Drug: Vortioxetine 10-20 mg · Drug: SSRI

  • Experimental
    SSRI

    licensed doses, encapsulated, orally

    Drug: Placebo · Drug: SSRI

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Digit Symbol Substitution Test (DSST): number of correct symbols

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change in Rey Auditory Verbal Learning Test (RAVLT) score: memory (delayed recall) and learning [acquisition])

    Time frame: Baseline to Week 8

  2. Change in Trail Making Test (TMT) score: TMT-A; speed of processing

    Time frame: Baseline to Week 8

  3. Change in TMT score: TMT-B; executive functioning

    Time frame: Baseline to Week 8

  4. Change in reaction time score: Choice Reaction Time (CRT); attention

    Time frame: Baseline to Week 8

  5. Change in reaction time score: Simple Reaction Time (SRT); psychomotor speed

    Time frame: Baseline to Week 8

  6. Change in Stroop Colour Naming Test (STROOP): incongruent score; executive functioning

    Time frame: Baseline to Week 8

  7. Change in STROOP: congruent score; speed of processing

    Time frame: Baseline to Week 8

  8. Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score

    Time frame: Baseline to Week 8

  9. Change in Hamilton Depression Rating Scale-17 (HAMD-17) total score

    Time frame: Baseline to Week 8

  10. Change in Clinical Global Impression - Severity of Illness (CGI-S)

    Time frame: Baseline to Week 8

  11. Clinical Global Impression - Global Improvement (CGI-I) score

    Time frame: Week 8

  12. Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score

    Time frame: Baseline to Week 8

  13. Number of adverse events

    Time frame: Baseline to Week 12

  14. Columbia Suicide Severity Rating Scale (C-SSRS) categorisation based on Columbia Classification Algorithm of Suicide Assessment (C-CASA) definitions (1, 2, 3, 4 and 7)

    Time frame: Baseline to Week 8

07

Study locations

17 sites
  • EE001
    Tallinn, Estonia
  • EE002
    Tallinn, Estonia
  • FI002
    Helsinki, Finland
  • FI003
    Helsinki, Finland
  • FI005
    Helsinki, Finland
  • FI001
    Kuopio, Finland
  • FI006
    Kupio, Finland
  • FI004
    Turku, Finland
  • DE002
    Berlin, Germany
  • DE001
    Bielefeld, Germany
  • DE005
    Bochum, Germany
  • DE003
    Frankfurt, Germany
  • DE004
    Mittweida, Germany
  • RS002
    Belgrade, Serbia
  • RS001
    Kragujevac, Serbia
  • SK003
    Levice, Slovakia
  • SK002
    Rimavska Sobota, Slovakia
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2014
First posted
Oct 31, 2014
Start
Oct 2014
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Last update
May 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02279953
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Oct 31, 2014
Start date
Oct 2014
Primary completion
Apr 2016
Completion
Apr 2016
Last update
May 24, 2017

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vortioxetine · SSRIs

Start the discussion